Shionogi to provide global access to its antibiotics, with focus on poor countries, as resistance fears grow
As the world faces a growing challenge of pathogens resistant to antibiotics, Shionogi and the GARDP have committed to an execution of a license and technology transfer agreement with the Clinton Health Access Initiative (CHAI).
According to Shionogi, the collaboration agreement will aim to increase access to antibiotics for countries around the world, with an emphasis on lower- and middle-income nations. The agreement will focus on cefiderocol, an antibiotic for the treatment of serious Gram-negative bacterial infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.